Does Wegovy Affect the Immune System?

What the STEP trials found — and what they didn't

When researchers designed the STEP clinical programme, which included the landmark STEP 1 trial published in the New England Journal of Medicine, immune suppression wasn't among the safety signals that emerged. Participants on semaglutide 2.4 mg did not show a pattern of increased serious infections compared with those on placebo, the finding you'd expect if the medicine were genuinely dampening immune defences.

What did emerge is more nuanced. GLP-1 receptor agonists appear to reduce levels of circulating inflammatory markers, including C-reactive protein. That's consistent with what happens when a person loses a meaningful amount of weight by any route, but some researchers believe the GLP-1 receptor itself may have a direct role in modulating inflammatory signalling, separate from weight loss. The broader picture of semaglutide and immune-related biology is still being studied.

The practical upshot: if you're worried that Wegovy might leave you catching every cold on the morning commute, the trial data don't support that concern. A weakened immune response was not a feature of the STEP programme. The NHS patient information for tirzepatide and semaglutide both acknowledge that injection-site reactions can occur, but these are a localised immune response to the injection, not a sign of systemic immune compromise.

Where a real, specific concern does arise

The picture changes if you already have an immune condition. People living with conditions such as rheumatoid arthritis, lupus or inflammatory bowel disease, or anyone taking medicines like methotrexate, biologics or systemic corticosteroids, are not automatically excluded from GLP-1 treatment, but the interaction between Wegovy and an already-altered immune landscape hasn't been studied in the same depth as the general population.

The MHRA's guidance on GLP-1 medicines recommends that all treatment decisions involve a clinical assessment of your full health picture, not a symptom-by-symptom checklist. The NHS patient information for semaglutide advises telling your prescriber about any ongoing conditions and all medicines you take before starting. That's not a formality, the prescriber is actively looking for interactions and contraindications that a self-assessment can miss.

A question our prescribers hear fairly often is whether semaglutide lowers immune function in people who've had organ transplants or who take rejection-prevention drugs. The short answer is: we don't know enough from trials to say it's safe in that context, which is exactly why a thorough clinical review matters. Wegovy sits in the fridge door next to the morning orange juice for most patients, but for someone on complex immunosuppression, the conversation with a prescriber needs to happen before the pen gets there.

Injection-site reactions and true allergic responses

The most common immune-related events recorded in Wegovy trials were local injection-site reactions: redness, itching or mild swelling at the point of injection. These are a normal localised immune response and typically resolve within a day or two. Rotating your injection site (abdomen, thigh and upper arm are all licensed locations) reduces how often they occur.

Systemic allergic reactions to semaglutide are rare. Signs that warrant urgent medical attention include a widespread rash, swelling of the face or throat, difficulty breathing, or a rapid heartbeat. If any of those occur, stop the injection and seek emergency help straightaway. You can also report any suspected side effect via the MHRA's Yellow Card scheme, which helps regulators track safety signals across the whole population using the medicine.

Separately, it's worth knowing how long semaglutide stays active in the body. Because it has a half-life of roughly one week, the medicine clears your system over several weeks after the last dose. If you needed to pause treatment before surgery or another medical procedure, that timing matters clinically.

Putting it in context: weight loss, inflammation and long-term immune health

Excess body weight is itself associated with chronic low-grade inflammation, which is part of why obesity raises the risk of cardiovascular disease, type 2 diabetes and certain cancers. Losing weight (by any means) tends to reduce that background inflammation. So from a population-level perspective, effective weight management treatment may benefit immune resilience over time, rather than harming it.

That broader context is laid out clearly in NHS England's guidance on weight-management injections, which describes the health rationale for GLP-1 medicines alongside the clinical criteria for their use. The evidence base continues to grow, particularly since the MHRA's January 2026 Drug Safety Update, which reviewed GLP-1 safety signals across the class, pancreatitis was the focus of that update, not immune function, which is itself a signal that immune suppression remains outside the primary safety concerns.

If you'd like to understand all the ways Wegovy might or might not weaken immune defences, the honest answer from the current evidence is: not in any clinically meaningful way for most people. For those with immune conditions, the conversation with a prescriber is essential. You can read more about semaglutide's properties and UK licensing on our semaglutide information page, or explore the range of clinically supervised weight-loss options available through nume.

If you're considering Wegovy and want to understand whether your health history makes it suitable, start a free consultation with our prescribers, who review every application personally the same day.